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Cervical cancer is the second most common
cancer among Tunisian women, and the
incidence rates vary by region. Three Tunisian
registries report age-standardized rates of 6.3/
105 in the central region, 5.4/105 in the north,
and 2.7/105 in the south. High-risk human papil-
lomavirus (HPV) types and their variants differ in
carcinogenic potential and geographic distri-
bution. The HPV type and variant distribution
could be a factor in the differing rates between
regions of Tunisia. Tumor tissue was collected
from 142 Tunisian cervical cancer patients.
Demographic and reproductive characteristics
of the patientswere abstracted fromcancer regis-
try and hospital records. HPV type and variant
analyses were performed using PCR-based
Luminex and dot-blot hybridization assays.
Eighty-threepercentof tumorswere infectedwith
at least one HPV type. European variants of
HPV16/18 were the most prevalent in tumors
from all three regions, with all HPV18 infections
and 64% of HPV16 infections being of European
lineage.Ahigher frequencyofHPV16waspresent
in Northern Tunisia (80%) than in Central (68%) or
Southern Tunisia (50%) (P ¼ 0.02). HPV18/45 was
significantly more common in adenocarcinomas
(50%) than in squamous cell carcinomas (11%)
(P ¼ 0.004). Frequent infection with European
HPV variants most likely reflects the history of
European migration to Tunisia. In addition to the
importance of understanding the variants of HPV
in Tunisia, behavioral and cultural attitudes
towards screening and age-specific infection rates
should be investigated to aid the development of
future vaccination and HPV screening programs
and policies. J. Med. Virol. 83:651–657,
2011.  2011 Wiley-Liss, Inc.




Cervical cancer is the second most common cancer
among women worldwide, with 80% of disease burden
occurring within developing countries [WHO/ICO,
2010]. Cervical cancer is estimated to be responsible
for 493,243 incident cases and 273,505 deaths annually,
amounting to 8% of the total burden of cancer among
womenworldwide [Castellsague et al., 2007;WHO/ICO,
2010]. Starting in the 1950s and 1960s, women in devel-
oped countries have benefited immensely from organ-
ized cytological screening programs, with mortality
rates falling to between 3/105 and 8/105 [Boyle and
Levin, 2008]. In developing countries where screening
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is less prevalent, mortality rates remain between 10/105
and 25/105, and incidence rates have been recorded to
exceed 25/105 [Boyle and Levin, 2008]. Cervical cancer
incidence in North Africa, where generally conservative
Muslim culture forbids sexual intercourse before
marriage, is considerably lower than not only other
regions of the world, but also other regions of Africa
[Castellsague et al., 2007]. The lower cervical cancer
incidence in North Africa is similar to that seen in
developed countries, despite much lower screening
coverage.
Tunisia has an especially low cervical cancer rate
within North Africa. At an age-standardized rate
(ASR) of 6.8/105, Tunisia’s cervical cancer rate is
nearly half of what is reported in Morocco (14.1) and
Algeria (10.4) [Ferlay et al., 2008; WHO/ICO, 2010].
Tunisia also has geographical variation of cervical
cancer rates between its three cancer registry regions,
with rates of 5.4/105 and 6.3/105 in the northern and
central registries, respectively [Korbi et al., 2008; Ben
Abdallah et al., 2009]. The southern registry, however,
reports anASR of only 2.7/105, excluding cervical cancer
from the top ten most common incident female cancers
in that region [Sellami etal., 2002].Tunisia’s prohibition
of marriage until age 17, the prohibition of polygamy,
and cultural stigma associated with sexual intercourse
before marriage most likely contribute to its low rates
of cervical cancer [Ben Abdallah, 1997; Maalej et al.,
2004]. However, Morocco and Algeria also both have a
minimum marriage age of 18 for women [An-Na’im,
2010] and similar cultural stigmas associated with
premarital sex.
Development of cervical neoplasia is known to be
causally associated with infection by high-risk
types of genital human papillomaviruses (HPV), mem-
bers of the genus Alphapapillomavirus of the family
Papillomaviridae [Bernard et al., 2010]. Of the over
120HPV types that have been identified, approximately
40 (mucosal) types of HPVhave been shown to infect the
anogenital tract of which approximately 13 can lead to
cancer, with HPV types 16 and 18 accounting for 2/3 of
cervical cancer cases worldwide [Schiffman et al., 2009;
Li et al., 2011].
HPV classification is based on sequence similarity
of the viral capsid (L1) gene. Types and variants are
defined as those strains with at least 90% similarity and
generally greater than 95% similarity, respectively
[Bernard et al., 2010]. Intra-typic variants of HPVs 16
and 18 have been the most well-studied and character-
ized to date. Four phylogenetic variant branches of
HPV16 have been identified, labeled as European
(including an Asian clade), Asian/American, African-1
and African-2 as they correspond to their most com-
monly occupied geographic regions [Chen et al., 2005].
African andnon-African variant lineages have also been
described for HPV18 [Chen et al., 2009]. These variants
are geographically distributed and suggest HPV has
coevolved with human population migration [Ho
et al., 1993]. Differences in carcinogenic potential have
also been shown for differentHPV16 variants, with non-
European variants being found more frequently in
aggressive and high-grade cervical cancer lesions
[Schiffman et al., 2010]. Studies in India, Thailand,
Brazil, Italy, Ecuador, Portugal, and Mongolia have
shown minor differences in the frequency of European
and non-European variants of HPV16 and 18
[Tornesello et al., 2004, 2008; Pista et al., 2007;
Chimeddorj et al., 2008; Junes-Gill et al., 2008; Pande
et al., 2008; Chopjitt et al., 2009; Pillai et al., 2009].
To date, little HPV variant research has been per-
formed in Tunisia or North Africa. Tunisia presents
an interesting population in which to study HPV var-
iants due to the historical record of population move-
ments through North Africa, as well as North Africa’s
striking intra- and inter-country incidence differences.
One would expect higher rates of European HPV16 due
to historical and continued travel both to and from
Tunisia and Europe. Thus, the aim of this study was
to investigate the types and variants of HPV among
Tunisian cervical cancer patients. An additional aim
was to study the relationship between HPV variants





The study was conducted at the Institut Salah Azaiez
(ISA) in Tunis, and theHôpital FarhatHached (HFH) in
Sousse, between May 2009 and April 2010.
Inclusion criteria for cases from both centers included
cancers that were primary, had a histopathologically
confirmed diagnosis of invasive cervical cancer and
had a paraffin-embedded cervical cancer tissue sample
available for sectioning. Cases for which cervical cancer
was a secondary cancer to another diagnosis, or had a
previoushistory of any cancer typewere excluded.Cases
were also excluded if themedical or registry record could
not be located.
ISA is the primary breast and cervical cancer referral
center in Tunisia, and is home to the population-based
Northern Tunisian Cancer Registry as well as a hospi-
tal-based registry [Ben Abdallah, 1997; Ben Abdallah
et al., 2009]. The pathology database of the Anatomy-
Pathology department of ISA was searched for all cer-
vical cancer diagnoses (excludingCIS) forwhich a tissue
sample was retrieved and analyzed at the institute in
2007 and 2008. Of the 262 cases identified through this
method, 27 had an inadequate tissue sample, 23medical
records could not be found, and 85 were diagnosed
outside of ISA and thus did not have a tissue sample
available for sectioning. Of the remaining 127 medical
records that were abstracted, 32 were excluded due to
clinical exclusion criteria, 1 paraffin block could not be
located, and 8 cases had come fromSousse governorates.
These eight were excluded due to the possibility of being
doubly included when later abstraction occurred at the
Central Tunisian Cancer Registry in Sousse. A total
of 86 samples were cut into 10 mm sections and
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transported back to the United States for HPV testing.
Of these 86 cases, 13were fromgovernorates included in
the Southern Tunisia Cancer Registry.
TheHFHAnatomy-Pathology department houses the
Central Tunisian Cancer Registry. Registry records
were used to extract the same reproductive and demo-
graphic information that was taken from ISA. Registry
datawere examined for all 204 cervical cancer diagnoses
included in the registry between 2002 and 2007. Of
these, 35 had been diagnosed outside the hospital and
thus had no pathology report associated with them.
Another 15 had no pathology record for unknown
reasons, 18 had no medical record information in the
registry, and 2 were from southern governorates that
had no way of being matched to the southern cases
already abstracted from ISA and thus were excluded.
Cases recorded in the ISA hospital registry and pathol-
ogy database do not overlap with cases in the HFH
registry. To ensure no overlap occurred, the governorate
of each case from ISA was checked to ensure that its
originwas in the northern registry region, and the same
was done for HFH cases and the central registry region.
Of the remaining 134 cases, 56 had an existing paraffin
block sample that could be sectioned for analysis. Ten-
micron sections were cut and transported to the United
States for HPV testing.
HPV Type and Variant Analyses
A total of 142 samples were transported to the Albert
Einstein College of Medicine. After DNA extraction and
PCR amplification of target sequences, Luminex and
dot-blot hybridization assays were used to identify
HPV types and variants. Probes for sequences within
E1, E2, E6, E7, and L2were used to identify variants for
HPV types 16 and 18. HPV16 andHPV18 variants were
classified as either European or non-European, as pre-
viously described [Chen et al., 2005, 2009]. Probes were
also used to detect HPV types 16, 18, 26, 30, 31, 33, 34,
35, 39, 45, 51, 52, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, 85,
and 97. Beta-globin amplification was included as a
measure of sample adequacy for PCR. Samples neither
PCR positive for HPV nor beta-globin were considered
inadequate for HPV testing. One case was excluded due
to suspected contamination during the cutting process.
The study was approved by the Institutional Review
Boards of the University of Michigan and the Albert
Einstein College of Medicine. All statistical analyses
were performed using SAS version 9.2. Associations
were tested using standard chi-square, Student’s t-test,
and odds ratio tests.
RESULTS
Of the 142 cases collected, 73 were from the northern
registry catchment area, 56 from the central registry
catchment area, and 13 from the southern registry
catchment area. The average age at cancer diagnosis
for all cases was 55 years, and differed significantly
between regions, reaching 58 years in Northern
Tunisia, 51 years in Central Tunisia, and 54 years
in Southern Tunisia (Table I). The average age at men-
struation and marriage also differed significantly
between regions, with the highest average age at men-
struation (15 years) being seen in Southern Tunisia,
while the highest age at marriage (20 years) was seen
in Northern Tunisia (Table I). There were no significant
regional differences in the age at first pregnancy, men-
opause, nor in a variety of reproductive variables.
Interestingly, the average duration of symptoms before
seeking treatment was 6 months for all 142 cases, and
reached a high of 36 months in one case, although no
difference was seen between regions (Table I).
The majority of cases were diagnosed at stages II and
III, representing 41%, and 33% of cases, respectively
(Table II). There were no differences seen between
regions in the frequencies of stage at diagnosis
(Table II). There was a statistically significant differ-
ence in histopathological status between regions, with
the highest rate of squamous cell carcinoma being
found in Central Tunisia (98%), followed by Northern
Tunisia (82%), and Southern Tunisia (69%) (P ¼ 0.01)
(Table II).
One case was excluded from HPV testing due to sus-
picions of contamination during the sectioning process.
Of the remaining 141 cases, 117 (83%) were infected
with at least one HPV type (Table III). Among all cases,
the frequency of infection with HPV16 and/or HPV18
was 70% (Table III). HPV16 andHPV18were present in
73% and 10% of cases infected with a single HPV type
(n ¼ 105) respectively (Table III). The frequency of
single infections with either HPV16 or HPV18 differed
significantly between the three registry regions, with a
higher frequency (80%) of HPV16 present in Northern
Tunisia than in Central Tunisia (67.6%) or Southern
Tunisia (50%) (P ¼ 0.02, Table III). HPV types 30, 31,
35, 39, 45, 56, 58, 66, 68, and 73 were also identified
(Table III). Among squamous cell carcinomas infected
with one HPV type (n ¼ 84), 76% were infected with
HPV16, and 5.9% were infected with HPV18 (data not
shown). Among adenocarcinomas infected with oneHPV
type (n ¼ 13), 46% were infected with HPV16, and 38%
were infected with HPV18 (data not shown). When
restricted to only those cases singly infected with
HPV16 or HPV18 and/or 45, HPV18/45 was significantly
more common in adenocarcinomas than squamous cell
carcinomas (50% vs. 11%, P ¼ 0.004, data not shown).
Multiple infectionswere identified in 12 cases (Table III).
All of the HPV18 and 64% of HPV16 positive cases
were of the European variant lineage (Table III). The
distribution of European variants among HPV16 single
infections was 66% in Northern Tunisia, 61% in Central
Tunisia, and 67% in Southern Tunisia (Table III). Cases
infected with a non-European variant of HPV16 had an
earlier average age at diagnosis than European variant
infections (53 years vs. 56 years, respectively) although
this difference was not significant. There was a higher
proportionofnon-EuropeanHPV16variants inStage III
cancers (50%) than Stage I cancers (38%), although this
difference was not significant and did not significantly
follow a linear trend.
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DISCUSSION
This is the first study to report on the distribution of
HPV16 and HPV18 variants in North Africa from all
three cancer registry regions of Tunisia. Eighty-three
percent of cases included in the studywere infectedwith
at least oneHPV type, and 70% of all caseswere infected
with either HPV16 or 18, including one case that was
infected with both. There was a slightly higher preva-
lence of non-European HPV16 in the Central Tunisia
region, where the incidence rate is highest, although
this difference was not significant. European variants
of HPV16 were found to be more prevalent than non-
European variants. It should be noted that this preva-
lence of HPV positivity among sampled cases is likely to
be an under-estimate of the actual prevalence of HPV
positivity. The process of preserving tissue in formalin-
fixed paraffin embedded blocks can result in a loss of
DNA integrity over time.
This study’s finding of HPV16/18 present in 70% of
Tunisian cases is comparable to the North African
HPV16/18 prevalence of 72.5% estimated by the HPV
Information Centre of the World Health Organization
(WHO) [WHO/ICO, 2010]. HPV16 was found to be sig-
nificantlymore frequent inNorthernTunisia than in the
other two regions. This could possibly be due to the low
rate of included adenocarcinomas from the Central
Tunisia region. Due to data storage differences between
registry regions, few adenocarcinomas were collected
from the Central Tunisia region. This is the most likely
reason for the observed significant difference in the
proportion of adenocarcinomas between regions shown
in Table I. The highest proportion of squamous cell
carcinomawas found in Central Tunisia (98%), followed
by Northern Tunisia (82%), and Southern Tunisia
(69%). These proportions differ slightly from the histo-
pathological frequencies reported in the registries,
which report squamous cell carcinoma frequencies of
78.2% in Central Tunisia, 75.9% in Northern Tunisia,
and 92.3% in Southern Tunisia [Korbi and Descoteaux-
Chatti, 1995; Sellami et al., 2002; Ben Abdallah et al.,
2009]. The overall frequency of squamous cell carcinoma
in all included cases in this study (86%) is not signifi-
cantly different from a Tunisian study of all cervical
cancer cases diagnosed in 1994 (91.23% squamous cell
carcinoma) [Maalej et al., 2004]. However, when data
from this studywere restricted to only those cases singly
infected with HPV16 or HPV18/45, HPV18/45 was sig-
nificantlymore common in adenocarcinomas (50%) than
in squamous cell carcinomas (11%, P ¼ 0.004), a com-
monly found association [Altekruse et al., 2003].
There have been very few HPV typing studies per-
formed among Tunisian women. A study in legal pros-
titutes working in Tunis, found anHPV16 prevalence of
38%, an HPV58 prevalence of 27%, an HPV82 preva-
lence of 15%, and a lack of any HPV18-infected cases
[De Marco et al., 2006]. An additional study from
Sousse, Tunisia, reported an HPV16 prevalence of
37% [Hassenet al., 2003].However, both of these studies
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were sampling only legal prostitutes. This study is the
first published to date to report HPV type prevalence
among diagnosed cervical cancer cases in Tunisian
women.
The results of this study show a slightly higher
frequency of HPV16 non-European variants present
in Central Tunisia than in the other two regions. As
non-European HPV16 variants are more often associ-
ated with more aggressive cancers diagnosed at later
stages [Sichero et al., 2007], it is possible that cervical
cancers caused by non-European HPV16 cause more
women in Central Tunisia to progress to cancers
TABLE III. HPV Type and Variant Frequencies Among HPV-Positive Cervical Cancer Cases, Tunisia, 2002–2008
HPV type All cases Northern Tunisia Central Tunisia Southern Tunisia P
All infections
16 85 (60%) 52 (91%) 27 (84%) 6 (67%) —
18 12 (9%) 5 (9) 4 (13%) 3 (33%)
16/18 1 (1%) 0 1 (3%) 0
Total 98 (70%) 57 32 9
Single infectionsa (n ¼ 105)
16 (all variants) 77 (73%) 48 (80%) 25 (68%) 4 (50%) 0.02
16Eb 41 (64%) 25 (66%) 14 (61%) 2 (67%) 0.92c
16NEb 23 (36%) 13 (34%) 9 (40%) 1 (33%)
18E 10 (10%) 4 (7%) 3 (8%) 3 (38%)
30 1 (1%) 1 (2%) 0 0
31 2 (2%) 1 (2%) 1 (3%) 0
35 1 (1%) 0 1 (3%) 0
39 1 (1%) 1 (2%) 0 0
45 4 (4%) 0 3 (8%) 1 (12%)
56 2 (2%) 1 (2%) 1 (3%) 0
58 1 (1%) 0 1 (3%) 0
66 3 (3%) 2 (3%) 1 (3%) 0
68 2 (2%) 1 (2%) 1 (3%) 0
73 1 (1%) 1 (2%) 0 0
Multiple infections
16/18 1 0 1 0
16/35 1 0 0 1
16/45 1 0 0 1
16/45/66 1 1 0 0
16/56 1 1 0 0
16/58 1 1 0 0
16/66 1 0 1 0
16/73 2 1 1 0
18/35 1 0 1 0
18/45 1 1 0 0
35/70 1 1 0 0
Significant at P ¼ 0.05 using chi-squared test for independence between the three regions, restricted to cases positive for HPV16 and HPV18.
aPercentages will not add up to 100 due to inclusion of HPV16 variants; see footnote below.
bPercentage represents percentage of each variant among cases positive for HPV16.
cChi-squared test for independence between the three regions, restricted to cases positive for HPV16E and HPV16NE.










Histopathological type (n ¼ 130)b
Squamous cell carcinoma 112 (86%) 59 (82%) 44 (98%) 9 (69%) 0.01
Adenocarcinoma 18 (14%) 13 (18%) 1 (2%) 4 (30%)
Stage at diagnosis (n ¼ 124)c
I 21 (17%) 11 (16%) 9 (20%) 1 (8%) 0.51
II 51 (41%) 30 (45%) 14 (32%) 7 (54%)
III 41 (33%) 21 (31%) 15 (34%) 5 (38%)
IV 11 (9%) 5 (8%) 6 (14%) 0
Menopausal status (n ¼ 94)
Pre-menopausal 13 (14%) 8 (15%) 4 (12%) 1 (12%) 0.95
Post-menopausal 81 (86%) 46 (85%) 28 (88%) 7 (88%)
Represents chi-squared test for independence between the three registry regions.Significant due to abstraction differences between the two data collection sites.
aIncludes HPV-negative, untyped, and multipally infected cases.
bDoes not include CIS, CNOS.
cDoes not include stage ¼ 0 (CIS).
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necessitating treatment. The frequencies of Stage III
and Stage IV cancers were slightly higher in Central
Tunisia thanNorthernTunisia, although staging differ-
ences between regions were not statistically significant.
It should also be noted that cases infected with non-
European variants of HPV16 had a slightly younger
age at diagnosis.
The primary strength of this study is that it is the first
to date to investigate HPV variants in North Africa or
Tunisia. Over 40 HPV types including all of the ‘‘high
risk’’ types were tested. Cervical cancer cases from
nearly all 27 governorates of Tunisia were represented,
giving asmany opportunities as possible to detect differ-
ences in HPV16 and 18 variant frequencies between
regions. Unfortunately, the collection of only 13 samples
from the Southern TunisianCancer Registry catchment
area limits any conclusions about the lower cervical
cancer rate seen in that part of the country.
This study also has a few limitations. Only confirmed
cervical cancer cases were included, and comparable
variants studies done in other countries typically
include a higher proportion of in situ and control cases.
Other limitations of the present study include a limited
sample size. Of the 262 identified cases at ISA and the
204 identified at HFH, only 86 (33%) and 56 (42%) could
be sampled forHPV testing, respectively. Sampled cases
as a percentage of the total number of women with
cervical cancer between 2002 and 2008 would be even
lower due to the fact that not all women suffering from
cervical cancer seek treatment at a health facility.
However, both of these centers are major referral cen-
ters for cervical cancer cases in their respective regions,
and it can be expected that they receive a high percent-
age of the women who do decide to seek care.
The paradox of Tunisia’s low cervical cancer rate has
not gone unnoticed, however, little research has been
done to investigate the phenomenon [Ben Abdallah,
1997; Hassen et al., 2003; Maalej et al., 2004].
Previous cervical cancer research in Tunisia has largely
been limited to behavioral studies related to screening
practices and access to care. Studies investigating
screening practices in Tunisia show a high acceptance
of cytological screening, but a very low frequency of
performance by physicians and midwives, and a low
frequency of uptake among women [Njah et al., 1994;
Hsairi et al., 2003]. The high prevalence of European
HPV variants most likely reflects the history of
European migration to Tunisia. In addition to the
importance of understanding the variants of HPV in
Tunisia, behavioral and cultural attitudes about screen-
ing and age-specific infection rates should be investi-
gated to aid the development of future vaccination and
HPV screening programs and policies.
The presence of high-risk HPV types in Tunisian
cervical cancer patients and the low uptake of regular
cervical cancer screening could make Tunisia a good
candidate country for one-time HPV testing imple-
mentation instead of cytological screening programs.
A 2009 study in India by Sankaranarayanan et al.
[2009] showed one-timeHPV testing to bemore effective
at reducing cervical cancer mortality and lowering the
rates of late-stage cervical cancer diagnosis than cyto-
logical smears or visual inspection with acetic acid.
As the majority of cervical cancer cases in this study
were diagnosed at Stage II or later, it appears that the
Tunisian population could benefit from screening using
HPV DNA testing. Additionally, the implementation of
HPV vaccination against HPV16/18 in Tunisia could
potentially eliminate 2/3 of the country’s cervical cancer
cases.
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